SCHEDULE 13G: Morgan Stanley Discloses Significant Stake in Apellis Pharmaceuticals, Inc.

Morgan Stanley and its subsidiary have filed a Schedule 13G, revealing beneficial ownership of 7.7% of Apellis Pharmaceuticals, Inc.'s common stock.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G with the SEC.
• The filing indicates that Morgan Stanley beneficially owns an aggregate of 9,592,751 shares of Apellis Pharmaceuticals, Inc. common stock.
• This ownership represents 7.7% of the total class of Apellis Pharmaceuticals, Inc. common stock.
• Morgan Stanley Capital Services LLC, as a subsidiary, beneficially owns 7,803,185 shares, accounting for 6.3% of the class.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing ownership, with no explicit positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral as it's a compliance-driven disclosure.

Positives

• A significant stake by a major institutional investor like Morgan Stanley can be interpreted as a vote of confidence in Apellis Pharmaceuticals, Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist position.

Risks

• The document contains a standard legal warning that intentional misstatements or omissions of fact constitute federal criminal violations (18 U.S.C. 1001).

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Apellis Pharmaceuticals, Inc.'s future performance or strategic direction from the issuer or the reporting entity.

Management Comments

• Christopher O'Hara, as Authorized Signatory for both Morgan Stanley and Morgan Stanley Capital Services LLC, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing reflects a routine disclosure of significant institutional investment in a publicly traded biotechnology company. Such disclosures are common as large financial institutions manage diverse portfolios, and crossing the 5% ownership threshold triggers mandatory reporting under SEC regulations.

Comparison to Industry Standards

• This is a standard Schedule 13G filing, which is a routine regulatory disclosure for institutional investors acquiring more than 5% of a company's stock without the intent to control. There are no specific comparable companies, projects, or results mentioned within this document to assess against industry standards.

Related Party Transactions

• Morgan Stanley Capital Services LLC, which beneficially owns 6.3% of Apellis Pharmaceuticals, Inc. common stock, is a wholly-owned subsidiary of Morgan Stanley, the parent holding company reporting 7.7% beneficial ownership.

Stakeholder Impact

• Shareholders of Apellis Pharmaceuticals, Inc. may view Morgan Stanley's significant stake as a positive signal of institutional confidence in the company's value and future prospects.

Key Dates

Keywords

Apellis Pharmaceuticals, Morgan Stanley, Institutional Ownership, Schedule 13G, Common Stock, Beneficial Ownership, Biotechnology, Pharmaceuticals, Investment